drugset / Trial / NCT07073469
Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial
Phase 3
Not yet recruiting
330 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary hypothesis being tested in this trial is that ischemic stroke patients in posterior circulation at 4.5 - 24 hours post onset of stroke will have improved clinical outcomes when given intravenous TNK compared to standard care.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2027-08-01
- Completion
- 2027-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |